Back to top
more

Amneal Pharmaceuticals (AMRX)

(Delayed Data from NSDQ)

$8.38 USD

8.38
1,835,514

+0.33 (4.10%)

Updated Aug 23, 2024 03:59 PM ET

After-Market: $8.38 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Amneal (AMRX) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Aclaris (ACRS) Begins Phase II Study on Eczema Candidate

by Zacks Equity Research

Aclaris (ACRS) initiates a phase IIa study on ATI-1777, for the treatment of moderate-to-severe atopic dermatitis.

Is AMNEAL PHARMACEUTICALS, INC. (AMRX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AMRX) Outperforming Other Medical Stocks This Year?

RedHill's (RDHL) RHB-204 Gets FDA Orphan Drug Designation

by Zacks Equity Research

RedHill (RDHL) gets Orphan Drug status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Amneal (AMRX) delivered earnings and revenue surprises of 30.00% and 3.73%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Amneal (AMRX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Amneal (AMRX) will provide financial updates when it reports second-quarter 2020 results.

Amneal Pharmaceuticals (AMRX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Amneal Pharmaceuticals (AMRX) closed the most recent trading day at $4.33, moving -0.69% from the previous trading session.

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amneal Pharmaceuticals (AMRX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Amneal Pharmaceuticals (AMRX) closed at $4.46, marking a +0.45% move from the previous day.

Can Amneal (AMRX) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Amneal Pharmaceuticals (AMRX) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Amneal Pharmaceuticals (AMRX) closed the most recent trading day at $4.86, moving +0.21% from the previous trading session.

Company News for Jul 13, 2020

by Zacks Equity Research

Companies in the news are: BNGO, AMRX, ALT, EXPR

Amneal Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Amneal Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Amneal Pharmaceuticals (AMRX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Amneal Pharmaceuticals (AMRX) closed the most recent trading day at $4.51, moving -0.66% from the previous trading session.

Pacira (PCRX) Provides Preliminary Results for Second Quarter

by Zacks Equity Research

Pacira (PCRX) reports preliminary results for the second quarter of 2020. The company's product sales are hurt by the COVID-19 pandemic. The stock fell in pre-market trading.

AMRX vs. COLL: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

AMRX vs. COLL: Which Stock Is the Better Value Option?

Profound Medical (PROF) Looks Good: Stock Adds 5.4% in Session

by Zacks Equity Research

Profound Medical (PROF) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

CytoDyn Signs MOU With NIH of Mexico for Coronavirus Study

by Zacks Equity Research

CytoDyn's (CYDY) shares rise more than 20% as it inks an MOU with NIH of Mexico to conduct a COVID-19 study on leronlimab.

Xeris Pharmaceuticals (XERS) in Focus: Stock Moves 6.8% Higher

by Zacks Equity Research

Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zogenix Gets FDA Nod for Dravet Syndrome Seizure Treatment

by Zacks Equity Research

Zogenix (ZGNX) gets FDA nod for Fintepla oral solution, CIV for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age or older.

Onconova Initiates Phase I/IIa Study on Lung Cancer Candidate

by Zacks Equity Research

Onconova (ONTX) starts investigator-initiated phase I/IIa study of oral rigosertib plus Bristol-Myers Squibb's Opdivo in advanced metastatic KRAS-mutated lung adenocarcinoma.

AMRX vs. COLL: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

AMRX vs. COLL: Which Stock Is the Better Value Option?

Jazz Pharmaceuticals (JAZZ) in Focus: Stock Moves 5.6% Higher

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Moving Average Crossover Alert: Amneal Pharmaceuticals

by Zacks Equity Research

Amneal Pharmaceuticals, Inc. (AMRX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Actinium Pharmaceuticals (ATNM) Jumps: Stock Rises 6.7%

by Zacks Equity Research

Actinium Pharmaceuticals (ATNM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.